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Introduction
============

Integrins are formed from α and β subunits, each with a large extracellular domain and a single, more C-terminal transmembrane domain. The subunits come together in a large interface between the α subunit β propeller domain and the β subunit β I domain to form the ligand-binding head. Other domains form upper and lower legs in each subunit to connect the head to the membrane. Integrins have an overall bent conformation in the low affinity state, with the bend between the upper and lower legs. Upon activation, integrins extend, and a major reorientation at the interface between the β I and hybrid domains occurs that is linked to remodeling of the ligand-binding site in the β I domain ([@bib30]). The β I domain has three metal ion--binding sites, with a Mg^2+^ ion in the central metal ion--dependent adhesion site (MIDAS) flanked by two Ca^2+^ ions, one of which is in a site termed adjacent to MIDAS (ADMIDAS). Structures of α~v~β~3~ and α~IIb~β~3~ bound to cyclic RGD-like peptides show binding across the α subunit β propeller interface with the β subunit I domain. The Asp side chain coordinates the Mg^2+^ ion at the β subunit I MIDAS, whereas the Arg side chain binds to Asp residues in the α subunit β propeller domain ([@bib50]; [@bib49]).

Early in hemostasis and thrombosis, the integrin α~IIb~β~3~ on platelets is activated and binds to its ligand fibrinogen. Fibrinogen is a dumbbell-shaped molecule ([Fig. 1 a](#fig1){ref-type="fig"}). Integrin α~IIb~β~3~ binds specifically to the distal ends of the dimeric fibrinogen molecule in a natively unstructured region at the C terminus of the γ subunit (γC peptide; [@bib51]). The large separation between the two α~IIb~β~3~-binding sites on fibrinogen of ∼440 Å is well suited for cross-linking of platelets, which results in platelet aggregation and formation of platelet plugs in hemostasis and thrombosis. In a later event in hemostasis, cleavage of peptides from the N termini of the fibrinogen α and β subunits stimulates assembly of fibrinogen into fibrin. Yet later, adjacent fibrinogen molecules within fibrin are cross-linked through their γC peptides by the factor XIIIa transglutaminase ([@bib19]; [@bib5]).

![**Fibrinogen and its C-terminal γ subunit sequences.** (a) Ribbon diagram of fibrinogen ([@bib51]) with α, β, and γ subunits in green, red, and blue, respectively, and natively unstructured C-terminal regions of the α and γ subunits ([@bib51]; [@bib14]) that contain RGD and KQAGDV sequences shown schematically as dashed lines. (b) The C-terminal sequence of the γ subunit in different species. Basic and acidic residues that are important for binding to fibrinogen as shown here for human and implicated for other species are shown in red. Gln and Lys residues known (human and lamprey; [@bib45]) or implicated (other species) to mediate fibrinogen cross-linking catalyzed by factor XIIIa transglutaminase are underlined. Sequence accession (GI) numbers of the relevant fibrinogen splice variants are 70906437, 73977998, 19527078, 61098186, 45384500, 120145, and 120143.](jcb1820791f01){#fig1}

One of the best established paradigms in integrin biology is the recognition of protein ligands through Arg-Gly-Asp (RGD) sequences, the majority of which are present within flexible loop regions. Eight vertebrate integrins, including α~IIb~β~3~ and α~v~β~3~, recognize RGD sequences in ligands, and crystal structures are beginning to reveal how RGD is recognized, at least in cyclic peptides ([@bib50]; [@bib49]). However, the γC region of fibrinogen lacks an RGD motif. Studies on synthetic peptides show specific binding of α~IIb~β~3~ to the γC C-terminal dodecapeptide, a gradual loss of activity when the dodecapeptide is truncated from its N terminus, and complete loss of activity when the C-terminal pentapeptide is removed. The minimal peptide with inhibitory activity was found to be the C-terminal pentapeptide, QAGDV ([@bib25], [@bib26]). Furthermore, removal of the γC QAGDV sequence but not of two RGD sequences in fibrinogen abolishes binding to α~IIb~β~3~ ([@bib16]; [@bib20]). Thus, although RGD peptides, including those corresponding to sequences in fibrinogen, can inhibit binding of α~IIb~β~3~ to fibrinogen, the γC peptide is the biologically important recognition site for α~IIb~β~3~ within fibrinogen. In contrast to α~IIb~β~3~, integrin α~v~β~3~ on endothelial cells binds to a distinct site containing an RGD motif in the fibrinogen α subunit ([@bib9]; [@bib43]; [@bib14]). This cooperative interaction between α~IIb~β~3~ and α~v~β~3~ integrins allows the platelet/fibrinogen thrombus formed by activation of α~IIb~β~3~ to be anchored on endothelium through α~v~β~3~ ([@bib9]; [@bib43]).

Whether RGD and γC peptides bind to distinct or similar sites on α~IIb~β~3~ is controversial. Several studies show competition for the same binding site ([@bib28]; [@bib39]; [@bib5]). Interestingly, although γC and RGD peptides were found to cross-compete, a γC dodecapeptide was photo--cross-linked only to the α~IIb~ subunit, whereas a RGD hexapeptide was cross-linked to both the α~IIb~ and β~3~ subunits ([@bib39]). Binding has been described of RGD and γC peptides to distinct, nonoverlapping, allosterically linked sites ([@bib21]). RGD and RGD-like peptides have also been described to bind to distinct sites on α~IIb~β~3~ ([@bib10]). Furthermore, γC peptide was reported to cross-link to an α~IIb~ site ([@bib11]) that is distal from the binding site for RGD shown in crystal structures ([@bib49]).

Because of the biological and clinical importance of the γC peptide in hemostasis and thrombosis, there has been great interest in determining its biologically relevant integrin-bound conformation. However, in multiple crystal structures of fibrinogen and its C-terminal γ subunit fragment, the γC peptide is disordered ([@bib38]; [@bib44]; [@bib52]; [@bib51]; [@bib27]). Crystals of the γC peptide fused to lysozyme or glutathione S--transferase reveal different conformations ([@bib13]; [@bib48]) that are unrelated to the integrin-bound conformation described here. Nuclear magnetic resonance measurements of γC interaction with α~IIb~β~3~ provided limited information ([@bib31]). In the absence of appreciation of the features important for specific recognition of γC by α~IIb~β~3~, pharmaceutical development of antithrombotics began with compounds with RGD or KGD motifs. Subsequent synthesis and screening then focused on obtaining compounds that were selective for α~IIb~β~3~ compared with other integrins that recognize RGD, such as α~v~β~3~ and α~5~β~1~ ([@bib40]). Two RGD-based drugs, a small molecule, tirofiban, and a cyclic peptide, eptifibatide, are currently used clinically to prevent thrombosis, and their complex structures with α~IIb~β~3~ have been determined ([@bib49]).

In this study, we investigate how the γC peptide and a related peptide containing the RGD sequence present in lamprey γC bind to α~IIb~β~3~. The results reveal the biologically important interface between γC peptide and α~IIb~β~3~ and unexpected features of the integrin recognition of ligands, including a direct role for ADMIDAS in ligand recognition.

Results
=======

Overall complex structure
-------------------------

We soaked human γC deca- and dodecapeptides into α~IIb~β~3~ headpiece/Fab crystals ([@bib49]). Examination of fibrinogen γ subunit sequences in a diverse range of vertebrates (fibrinogen is found only in vertebrates) revealed that RGD is found in γC in frog and lamprey ([Fig. 1 b](#fig1){ref-type="fig"}). This observation, which, to our knowledge, is previously unremarked and therefore was a surprise to us, suggests an obvious evolutionary pathway from promiscuous integrin recognition of RGD in the primordial jawless vertebrate the lamprey to monospecific integrin recognition of non-RGD sequences in most higher vertebrates. Therefore, for comparison to human γC, we also soaked crystals with chimeric deca- or dodecapeptides containing the RGD sequence present in lamprey γC ([Fig. 1 b](#fig1){ref-type="fig"}). Structures were determined at 2.4--2.8-Å resolution ([Table I](#tbl1){ref-type="table"}), and previous structures with antagonists were rerefined to lower R~free~ ([Table II](#tbl2){ref-type="table"}). The structures contain the β propeller domain in the α~IIb~ subunit; the I, hybrid, plexin-semaphorin integrin, and integrin EGF-like (I-EGF) domain 1 in the β~3~ subunit; 15 carbohydrate residues; and bound ligand and Fab. The structures all have an open headpiece (i.e., with the hybrid domain swung out) and the β I domain in the high affinity state ([@bib49])

###### α~IIb~β~3~ γC peptide complex x-ray diffraction and refinement data

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Peptide sequence                                                   HHLGGAKQAGDV                                 LGGAKQAGDV                                   HHLGGAKQRGDV                                LGGAKQRGDV
  ------------------------------------------------------------------ -------------------------------------------- -------------------------------------------- ------------------------------------------- --------------------------------------------
  Space group                                                        P3~2~21                                      P3~2~21                                      P3~2~21                                     P3~2~21

  Unit cell (a, b, c) (Å)                                            148.3, 148.3, 176.6                          148.4, 148.4, 177.2                          148.5, 148.5, 176.4                         148.3, 148.3,176.8

  α, β, γ (degree)                                                   90, 90, 120                                  90, 90, 120                                  90, 90, 120                                 90, 90, 120

  Wavelength (Å)                                                     1.07223                                      1.07223                                      1.07223                                     1.07223

  Resolution (Å)                                                     50--2.5                                      50--2.8                                      50--2.6                                     50--2.4

  Number of reflections (total/unique)                               557,015/77,023                               362,650/55,536                               416,764/68,878                              609,049/87,704

  Completeness (%)                                                   99.8/100[b](#tblfn2){ref-type="table-fn"}    99.4/99.6[b](#tblfn2){ref-type="table-fn"}   98.5/87.4                                   99.7/99.0[b](#tblfn2){ref-type="table-fn"}

  I/σ (I)                                                            17.6/3.5[b](#tblfn2){ref-type="table-fn"}    16.2/2.8[b](#tblfn2){ref-type="table-fn"}    19.1/2.2[b](#tblfn2){ref-type="table-fn"}   17.3/2.3[b](#tblfn2){ref-type="table-fn"}

  R~merge~ (%)                                                       8.6/55.2b[b](#tblfn2){ref-type="table-fn"}   10.5/62.3[b](#tblfn2){ref-type="table-fn"}   8.5/43.3                                    9.0/56.9[b](#tblfn2){ref-type="table-fn"}

  Number of atoms\                                                   10,538/1,043/205                             10,446/557/205                               10,515/1,332/205                            10,537/1,142/205
      (protein/water/other)                                                                                                                                                                                

  R~msd~ bond lengths (Å)                                            0.006                                        0.006                                        0.007                                       0.007

  R~msd~ bond angles (degree)                                        1.0                                          1.0                                          1.0                                         1.0

  R~work~ (%)                                                        14.8                                         15.6                                         14.1                                        14.8

  R~free~ (%)                                                        19.0                                         20.4                                         19.0                                        19.3

  Ramachandran statistics\                                           96.9/3.0/0.1                                 96.5/3.4/0.1                                 97.1/2.6/0.2                                97.1/2.7/0.2
      (% favored/allowed/outlier)[a](#tblfn1){ref-type="table-fn"}                                                                                                                                         

  PDB code                                                           2VDO                                         2VDP                                         2VDQ                                        2VDR
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

R~merge~ = Σ~H~ Σ~i~ \|I*~i~*(*h*) − \<I(*h*)\>\|/Σ~H~Σ~i~ I~i~(*h*), where I~i~(*h*) and \<I(*h*)\> are the ith and mean measurement of the intensity of reflection, *h*. R~work~ = Σ~H~\|\|*F*~obs~ (*h*)\| − \|*F*~calc~ (*h*)\|\|/Σ~H~\|*F*~obs~ (*h*)\|, where *F*~obs~ (*h*) and *F*~calc~ (*h*) are the observed and calculated structure factors, respectively. No I/σ cutoff was applied. R~free~ is the R value obtained for a test set of reflections consisting of a randomly selected 5% subset of the data set excluded from refinement.

Determined with RAMPAGE ([@bib29]).

These numbers correspond to the last resolution shell.

###### Rerefined α~IIb~β~3~ complex x-ray diffraction and refinement data

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Ligand                                                             Native1                                      Native2                                     Tirofiban                                    Eptifibatide                                 L-739758
  ------------------------------------------------------------------ -------------------------------------------- ------------------------------------------- -------------------------------------------- -------------------------------------------- --------------------------------------------
  Space group                                                        P3~2~21                                      P3~2~21                                     P3~2~21                                      P3~2~21                                      P3~2~21

  Unit cell (a, b, c) (Å)                                            148.9, 148.9, 176.1                          148.9, 148.9, 176.4                         148.6, 148.6, 177.2                          149.6, 149.6, 175.7                          149.2, 149.2, 176.2

  α, β, γ (degree)                                                   90, 90, 120                                  90, 90,120                                  90, 90, 120                                  90, 90, 120                                  90, 90, 120

  Wavelength (Å)                                                     0.9793                                       0.9793                                      0.9760                                       0.9760                                       0.9793

  Resolution (Å)                                                     50--2.8                                      50--2.75                                    50--2.9                                      50--2.9                                      50--3.1

  Number of reflections\                                             400,460/55,875                               442,121/62,512                              330,745/50,662                               357,439/50,647                               263,308/41,586
      (total/unique)                                                                                                                                                                                                                                    

  Completeness (%)                                                   99.9/99.8[b](#tblfn4){ref-type="table-fn"}   99.9/100[b](#tblfn4){ref-type="table-fn"}   99.7/98.2[b](#tblfn4){ref-type="table-fn"}   100/100[b](#tblfn4){ref-type="table-fn"}     99.8/99.7[b](#tblfn4){ref-type="table-fn"}

  I/σ (I)                                                            14.0/3.1[b](#tblfn4){ref-type="table-fn"}    20.0/3.0[b](#tblfn4){ref-type="table-fn"}   12.1/2.0[b](#tblfn4){ref-type="table-fn"}    14.9/2.7[b](#tblfn4){ref-type="table-fn"}    12.1/2.7[b](#tblfn4){ref-type="table-fn"}

  R~merge~ (%)                                                       13.0/68.1[b](#tblfn4){ref-type="table-fn"}   9.6/59.8[b](#tblfn4){ref-type="table-fn"}   13.9/57.8[b](#tblfn4){ref-type="table-fn"}   11.7/61.5[b](#tblfn4){ref-type="table-fn"}   14.0/55.8[b](#tblfn4){ref-type="table-fn"}

  Number of atoms\                                                   10,404/612/210                               10,461/1,129/210                            10,363/355/235                               10,385/364/223                               10,348/98/240
      (protein/water/other)                                                                                                                                                                                                                             

  R~msd~ bond lengths (Å)                                            0.005                                        0.006                                       0.005                                        0.005                                        0.007

  R~msd~ bond angles (degree)                                        0.9                                          1.0                                         0.9                                          0.9                                          1.0

  R~work~ (%)                                                        16.1                                         14.4                                        16.7                                         16.3                                         18.1

  R~free~ (%)                                                        20.4                                         19.1                                        20.6                                         21.3                                         22.0

  Ramachandran statistics\                                           97.3/2.5/0.2                                 97.2/2.5/0.3                                96.5/3.3/0.2                                 96.8/2.9/0.2                                 96.5/3.3/0.2
      (% favored/allowed/outlier)[a](#tblfn3){ref-type="table-fn"}                                                                                                                                                                                      

  Obsolete PDB code                                                  1TY3                                         1TXV                                        1TY5                                         1TY6                                         1TY7

  New PDB code                                                       2VDK                                         2VDL                                        2VDM                                         2VDN                                         2VC2
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

R~merge~ = Σ~H~ Σ~i~ \|I*~i~*(*h*) − \<I(*h*)\>\|/Σ~H~Σ~i~ I~i~(*h*), where I~i~(*h*) and \<I(*h*)\> are the ith and mean measurement of the intensity of reflection, *h*. R~work~ = Σ~H~\|\|*F*~obs~ (*h*)\| − \|*F*~calc~ (*h*)\|\|/Σ~H~\|*F*~obs~ (*h*)\|, where *F*~obs~ (*h*) and *F*~calc~ (*h*) are the observed and calculated structure factors, respectively. No I/σ cutoff was applied. R~free~ is the R value obtained for a test set of reflections consisting of a randomly selected 5% subset of the data set excluded from refinement.

Determined with RAMPAGE ([@bib29]).

These numbers correspond to the last resolution shell.

The γC peptide binds at the interface between the α~IIb~ β propeller and β~3~ I domains ([Fig. 2 a](#fig2){ref-type="fig"}). The binding site overlaps with, but is more extensive on both the α and β subunits, than previously described for cyclic RGD peptides ([@bib50]; [@bib49]). The contacts on the β~3~ subunit include not only MIDAS but also a novel water-mediated coordination of the γC C terminus with ADMIDAS, as described in more detail in the next section. The γC peptide contacts with α~IIb~ lie in a groove between two long loops that connect blades (β sheets of the α~IIb~ β propeller) 2 and 3 and blades 3 and 4. The cap subdomain of the β propeller ([@bib49]) forms one side of this groove ([Fig. 2 b](#fig2){ref-type="fig"}). In the region of the γC peptide N terminal to residue 404, extension along the groove is blocked by contact of γC residue Leu-402 with a neighboring molecule in the crystal lattice, and residues 400--403 have weak electron density and extend toward solvent. Therefore, we limit our structural analysis to γC octapeptide residues 404--411, which show strong electron density in omit maps, intimately contact α~IIb~β~3~ ([Fig. 2](#fig2){ref-type="fig"} and [Fig. 3 a](#fig3){ref-type="fig"}), and have essentially identical conformations in crystals soaked with γC peptides 400--411 and 402--411 ([Table I](#tbl1){ref-type="table"}).

![**The binding pocket for the γC peptide.** (a) Overview. (b) Detail. α~IIb~β~3~ and 10E5 Fab are shown as solvent-accessible surfaces, with the γC peptide shown in spheres (a) or sticks (b). Lys-406 and Asp-410 are the most buried residues. The surface at the ADMIDAS metal is colored purple (as is that at the MIDAS, which is not visible), and the water coordinating the Val-411 α-carboxyl to the ADMIDAS is a red sphere. Figures were made with Pymol (DeLano Scientific).](jcb1820791f02){#fig2}

![**Binding of the linear γC and RGD chimera peptides and comparison with cyclic peptides.** Ligand, α subunit, and β subunit are shown in green, light blue, and beige, respectively, with O, N, and S atoms in red, blue, and yellow, respectively. Water molecules are red spheres. Ca^2+^ ions are gold spheres, and Mg^2+^ ions (a--c) or Mn^2+^ ions (d) are silver spheres. Fc-Fo omit maps after refinement in the absence of ligands and the displayed water molecules are contoured at 3σ. The complexes are α~IIb~β~3~ (a--c) with γC dodecamer (a) or chimera decamer (b) peptides, disulfide-cyclized eptifibatide peptide (c), or α~v~β~3~ with backbone-cyclized cilengitide peptide (d; [@bib50]). One-letter code is used for residues except for homoarginine (Har). Residue C7 in eptifibatide (c) is amidated.](jcb1820791f03){#fig3}

Surface representations of the binding site show not only the groove in which the γC peptide lies but two deeper pockets within this groove ([Fig. 2 b](#fig2){ref-type="fig"}). The penultimate residue in the γC peptide, Asp-410, buries its side chain in a pocket at the MIDAS Mg^2+^ ion in the β~3~ I domain. The surface at the MIDAS Mg^2+^ ion is not visible in this view, which is in contrast to the surface at the ADMIDAS Ca^2+^ ion ([Fig. 2 b](#fig2){ref-type="fig"}, purple), which is much more solvent exposed. The other deep pocket, on the α~IIb~ side of the interface, is occupied by Lys-406 of the γC peptide ([Fig. 2 b](#fig2){ref-type="fig"}). This is the same pocket that is occupied by the Arg side chain of RGD peptides.

[Fig. 3](#fig3){ref-type="fig"} compares the binding modality of the γC peptide ([Fig. 3 a](#fig3){ref-type="fig"}) to that of RGD-like peptides ([Fig. 3, b--d](#fig3){ref-type="fig"}). We first will describe the RGD peptide-binding modality and then return to γC and compare it with RGD. The A408R substitution yielding the lamprey-like RGD motif in the chimera peptide γC ([Fig. 1 b](#fig1){ref-type="fig"}) results in retention of α~IIb~β~3~ antagonist activity ([@bib26]). In the chimera γC peptide, the Arg-408 side chain extends directly into the α~IIb~-binding pocket ([Fig. 3 b](#fig3){ref-type="fig"}) and displaces Lys-406, which binds in this pocket in the γC peptide ([Fig. 3 a](#fig3){ref-type="fig"}).

In contrast to previous integrin structures with cyclized peptides ([@bib50]; [@bib49]), the α~IIb~β~3~ complexes with the chimera peptides show how an RGD peptide unconstrained by cyclization binds to an integrin and provide the best comparison with the γC peptide. The RGD tripeptide adopts a highly extended conformation across the integrin α/β intersubunit interface ([Fig. 3 b](#fig3){ref-type="fig"}). The Arg and Asp side chains extend in opposite directions, and the backbone in between is also extended. The conformation of the ligand backbone is stabilized as it crosses the interface between the α~IIb~ and β~3~ subunits by two previously unremarked water molecules with strong density that are held in place by hydrogen bonds to the side chain of α~IIb~ Asp-232 and backbone of β~3~ Ala-218 and that hydrogen bond to the carbonyl oxygen of the Arg of RGD ([Fig. 3 b](#fig3){ref-type="fig"}). The Arg side chain of RGD forms a charged hydrogen bond to α~IIb~ residue Asp-224 and also forms a hydrogen bond to an α~IIb~ backbone carbonyl. The Asp side chain of RGD directly coordinates to the MIDAS Mg^2+^ cation and is further satisfied by three hydrogen bonds to the β~3~ backbone and one to the side chain of β~3~ Asn-215. The same geometry at the Asp is seen for all α~IIb~β~3~ complexes, which are in the high affinity state ([Fig. 3, a--c](#fig3){ref-type="fig"}). Only one of the four Asp hydrogen bonds are seen at the Asp of the α~v~β~3~ complex ([Fig. 3 d](#fig3){ref-type="fig"}) because it has a closed headpiece, and the two backbone nitrogens of the β~1~-α~1~ loop have not moved within hydrogen bonding distance; furthermore, the side chain of Asn-215 should probably be flipped.

By reducing the loss of peptide entropy upon binding, cyclization can increase affinity and is therefore widely adopted in drug development. Eptifibatide is a seven-residue L peptide that is cyclized with a disulfide bond, contains homoarginine-Gly-Asp in place of RGD, and is in clinical use for prevention of thrombosis ([Fig. 3 c](#fig3){ref-type="fig"}). Eptifibatide binds similarly to RGD, and the carbonyl oxygen of its homoarginine residue similarly hydrogen bonds to the waters held in place by α~IIb~ Asp-232 ([Fig. 3 c](#fig3){ref-type="fig"}). However, cyclization pins back the homoarginine Cα and N atoms so that the Cγ atom of homoarginine is in a similar position to the Cβ atom of Arg, explaining the requirement for the one-carbon longer homoarginine side chain ([Fig. 3, b and c](#fig3){ref-type="fig"}).

Cilengetide, an α~v~β~3~ antagonist, is a five-residue peptide that contains RGD, *N*-methyl-Val, and [d]{.smallcaps}-Phe ([Fig. 3 d](#fig3){ref-type="fig"}). The Arg of cilengitide forms a charged hydrogen bond to α~v~ residue Asp-218. Cilengetide is cyclized through its peptide backbone in a considerably smaller ring than epitifibatide. Tight cyclization, which is important to prevent binding to α~IIb~β~3~ ([@bib40]; [@bib17]), pulls the Arg backbone back away from the α~v~ subunit and helps place the Arg side chain further above the subunit than the Arg or homoarginine of α~IIb~ ligands, as appropriate for the shallower α~v~ binding pocket ([Fig. 3 d](#fig3){ref-type="fig"}).

The fibrinogen γC peptide complex with α~IIb~β~3~ reveals that γC residue Lys-406 forms a charged hydrogen bond to α~IIb~ residue Asp-224 ([Fig. 3 a](#fig3){ref-type="fig"}). Therefore, γC Lys-406 is functionally equivalent to the Arg of RGD ([Fig. 3 b](#fig3){ref-type="fig"}) and the homoarginine of eptifibatide ([Fig. 3 c](#fig3){ref-type="fig"}). Furthermore, the Ala-Gly-Asp moiety of γC has a conformation identical to that of Arg-Gly-Asp, and the carbonyl oxygen of Ala-408 hydrogen bonds to the two water molecules held in place by α~IIb~ Asp-232 at the interface with the β~3~ subunit in a geometry identical to that seen for the Arg and homoarginine carbonyl oxygens of RGD and eptifibatide ([Fig. 3, a--c](#fig3){ref-type="fig"}). Indeed, the Cβ atoms of Ala-408 of γC and the Arg of RGD occupy identical positions ([Fig. 3, a and b](#fig3){ref-type="fig"}). The critical difference between the γC peptide-- and RGD peptide--binding modalities is the backbone turn at γC residue Gln-407, which orients the N-terminal portion of the γC peptide into the groove formed by the long loops that connect α~IIb~ β propeller blades 2 and 3 and blades 3 and 4 ([Fig. 3 a](#fig3){ref-type="fig"}). The backbone turn at γC Gln-407 enables the γC Lys-406 side chain to enter the α~IIb~ binding pocket from a markedly different location than the Arg side chain of RGD ([Fig. 3, a and b](#fig3){ref-type="fig"}). The last few atoms of the Lys-406 side chain turn to approach α~IIb~ Asp-224 from a similar direction as Arg ([Fig. 3, a and b](#fig3){ref-type="fig"}). A 15-fold loss of potency upon substitution of Lys-406 with Arg ([@bib26]) is explicable by the inability of the planar guanido group of Arg to similarly turn. Hydrophobic α~IIb~ residues Tyr-190, Leu-192, and Phe-231 line the pocket and contact the aliphatic portion of the γC Lys-406 side chain and the Ala-408 side chain. γC residues Gly-404, Ala-405, and Lys-406 fill the groove between adjacent β propeller blades and form backbone--backbone and backbone--side chain hydrogen bonds to α~IIb~ residues Asp-159 and Ser-226 ([Fig. 3 a](#fig3){ref-type="fig"}). γC residues Gly-404 and Ala-405 also seal the binding pocket for the Lys-406 side chain, with γC residue Gly-404 forming a backbone hydrogen bond to the γC Lys-406 side chain.

ADMIDAS coordination
--------------------

An important and unexpected observation is that the free carboxyl group of the γC C-terminal residue Val-411 coordinates the β~3~ I domain ADMIDAS calcium ion through an intermediate water molecule with strong density ([Fig. 3 a](#fig3){ref-type="fig"}). The contribution of this coordination to ligand binding is demonstrated by the finding that amidation of the α-carboxyl group decreases by sixfold the potency of γC peptides in inhibiting fibrinogen binding to α~IIb~β~3~ ([@bib26]). An identical ADMIDAS coordination is seen with the chimera QRGDV peptide ([Fig. 3 b](#fig3){ref-type="fig"}). The significance of this observation, the notable similarity in backbone positions of Val-411 of the γC and chimera peptides, and the equivalent residue in eptifibatide, Trp-5 ([Fig. 3, a--c](#fig3){ref-type="fig"}), is discussed in the next section.

Discussion
==========

Specific recognition of the fibrinogen γC peptide by α~IIb~β~3~
---------------------------------------------------------------

Our structures of γC peptides bound to α~IIb~β~3~ reveal the interface that is biologically important for the binding of fibrinogen to activated integrin α~IIb~β~3~ on platelets. This binding event, in turn, leads to cross-linking of platelets by fibrinogen and the formation of platelet plugs in hemostasis and thrombosis. Whereas Arg-Gly-Asp binds to eight different integrins, the fibrinogen γC peptide binds only to α~IIb~β~3~.

Our γC peptide complex with α~IIb~β~3~ reveals the basis for binding of platelet α~IIb~β~3~ and endothelial α~v~β~3~ to distinct sites in fibrinogen, enabling these integrins to have complementary rather than competitive functions in hemostasis ([Fig. 1 a](#fig1){ref-type="fig"}; [@bib9]; [@bib43]). The interface on the integrin α subunit occupied by the γC peptide is much larger than that occupied by RGD. γC residues Gly-404, Ala-405, Lys-406, and Ala-408 all interact with α~IIb~. In contrast, in the linear RGD chimera peptide, only Arg-408 binds to the α~IIb~ subunit. This much more extensive interface with γC enables specific differences between α~IIb~ and other integrin α subunits to be recognized as good contacts made by α~IIb~ and clashes made by α~v~. The shallower and narrower binding site in the α~v~ subunit precludes binding of the KQAGDV moiety using the α~IIb~β~3~-bound conformation. For example, α~v~ Ala-215 and Asp-218 would both clash with KQAGDV. These results show why the γC peptide does not bind to α~v~.

In contrast, RGD does bind to α~IIb~β~3~, and, therefore, the selectivity of α~IIb~β~3~ for the γC site over RGD in fibrinogen ([@bib9]; [@bib43]) must reflect a higher affinity for γC. Fibrinogen lacking the γC QAGDV pentapeptide fails to bind α~IIb~β~3~ and results in bleeding disorders in mice ([@bib16]; [@bib20]). This emphasizes the absolutely critical role of the γC peptide in recognition by α~IIb~β~3~; however, it does not mean that the γC peptide is responsible for all of α~IIb~β~3~\'s affinity for fibrinogen. Indeed, α~IIb~β~3~ has 100-fold higher affinity for fibrinogen than for the γC octapeptide ([@bib24], [@bib25]). Mutagenesis studies show that the binding site on the α~IIb~ β propeller domain includes, but is larger than, the γC octapeptide--binding site defined here ([@bib23]; [@bib49]). The 10E5 Fab binds within this region of the α~IIb~ β propeller that is important in fibrinogen binding and blocks binding of fibrinogen but not the octapeptide to α~IIb~β~3~. Because the N terminus of the octapeptide extends toward the 10E5 Fab--binding site ([Fig. 2](#fig2){ref-type="fig"}), it is tempting to speculate that regions N terminal to the γC peptide, including well-folded γC module residues 144--392, also bind to α~IIb~β~3~ and, together with the γC peptide, account for the higher biological affinity of α~IIb~β~3~ for fibrinogen than for RGD peptides. Such other regions of the γC domain may also account for the retention of clot-retraction activity by fibrinogen deleted in the QAGDV pentapeptide ([@bib20]). Integrin binding or inhibition of clot retraction has been demonstrated using portions of γC N terminal to KQAGDV made in *Escherichia coli* ([@bib32]; [@bib53]; [@bib37]); however; *E. coli* γC fragments also express integrin-binding sites that are not present on native fibrinogen ([@bib1]).

Multiple crystal structures of fibrinogen and its fragments show that γ chain residues 404--411 are disordered and that residues 393--403, when ordered, completely differ in conformation from one crystal lattice to another ([@bib38]; [@bib44]; [@bib52]; [@bib51]; [@bib27]). Previous intense and creative efforts using carrier protein-driven crystallization ([@bib13]; [@bib48]) failed to reveal the biologically relevant conformation of the γC peptide.

Our structures reveal the conformation that γC residues 404--411 adopt when bound to α~IIb~β~3~. Although not inconsistent with the previous conclusion that QAGDV represents a minimal recognition unit in γC, our structure resolves the conundrum that QAGDV lacks a basic residue by demonstrating that Lys-406 fulfills a function similar to the Arg in RGD and that the KQAGD motif in γC occupies the same site as RGD. Residues Gly-404 and Ala-405 also appear to have an important role in sealing the binding pocket for Lys-406 in the α~IIb~ groove.

In the absence of information on how the γC peptide binds α~IIb~β~3~, development of the two currently approved small molecule α~IIb~β~3~ therapeutics, tirofiban and eptifibatide, proceeded from RGD and barbourin, respectively ([@bib40]). Barbourin is a disintegrin with two highly unusual properties for a disintegrin: specificity for α~IIb~β~3~ and KGD in place of the RGD motif ([@bib41]). Lysine has a side chain with Cβ, Cγ, Cε, and Nζ atoms. The Arg side chain has Cβ, Cγ, and Cδ atoms and a guanido group with Nε, Nη~1~, Nη~2~, and Cζ atoms. The three N atoms of Arg give it versatility for hydrogen bonding. Although the Arg side chain readily forms charged hydrogen bonds through different guanido nitrogens to α~IIb~--Asp-224 in [Fig. 3 b](#fig3){ref-type="fig"} and α~v~--Asp-218 in [Fig. 3 d](#fig3){ref-type="fig"}, it is easy to imagine how a Lys in a similar position might better form a hydrogen bond to α~IIb~--Asp-224 than to α~v~--Asp-218. The final drug developed from barbourin, eptifabitide, has a homoarginine side chain in place of lysine ([Fig. 3 c](#fig3){ref-type="fig"}). This drug binds very similarly to RGD ([Fig. 3 b](#fig3){ref-type="fig"}) and quite differently from the γC peptide, in which the Lys side chain enters the α~IIb~ binding pocket from a completely different direction ([Fig. 3 a](#fig3){ref-type="fig"}). Thus, drug design starting from KGD ironically resulted in an RGD-like antagonist with a binding modality very different from KQAGDV.

The γC complex structure provides new insights for the development of second generation integrin antagonists. Mimicking the novel route into the α~IIb~ binding pocket adopted by the Lys of the KQAGDV motif should enable development of new classes of highly specific α~IIb~β~3~ antithrombotics. Furthermore, mimicking the novel interaction with the ADMIDAS metal ion is attractive for improving the specificity and affinity of antagonists to a wide range of integrins.

The finding that the γC peptide--binding site completely overlaps the RGD peptide--binding site definitively resolves the long-standing controversy about whether these peptides compete for binding to the same site or bind to distinct sites ([@bib28]; [@bib39]; [@bib11]; [@bib21]; [@bib5]). Furthermore, our studies explain previous observations of photo--cross-linking of the γC dodecapeptide peptide to only the α~IIb~ subunit and of an RGD hexapeptide to both the α~IIb~ and β~3~ subunits, with cross-competition by RGD and γC peptides, respectively ([@bib39]). Both peptides appeared to have the radiolabeled, photoactivatable reagent attached to their N-terminal α-amino groups. The exclusive labeling of α~IIb~ by the reagent attached to γC His-400 is consistent with the position of Gly-404 in our structures in the α~IIb~ β propeller groove and also with further extension in the N-terminal direction in this groove. In contrast, labeling of both the α~IIb~ and β~3~ subunits by the reagent attached to the residue before the Arg of RGD is consistent with the position of the corresponding Gln-407 residue at the interface between the α~IIb~ and β~3~ subunits in the chimera deca- and dodecamer structures.

A role for ADMIDAS in ligand binding
------------------------------------

Previous crystal structures and mutation of MIDAS-coordinating residues have shown that the MIDAS metal ion has a direct role in ligand binding ([@bib30]). In contrast, the ADMIDAS metal ion has been shown to have a regulatory role in ligand binding. During conversion from the low affinity, closed conformation to the high affinity, open conformation of the integrin headpiece, remodeling of the β~1~-α~1~ loop that coordinates to the ADMIDAS metal ion shifts the position of this metal ion by 3 Å ([@bib49]). Ca^2+^ and Mn^2+^ compete for binding to ADMIDAS, resulting in inhibition or stimulation of ligand binding, respectively ([@bib7]). We note that physiologically and in the current structures, Ca^2+^ is present at ADMIDAS ([@bib49]) and that coordination is pentagonal bipyramidal, with seven oxygen ligands as typically seen for Ca^2+^. ADMIDAS mutations augment ligand binding by integrins α~4~β~7~ and α~L~β~2~ ([@bib7], [@bib8]) and, in contrast, inhibit ligand binding by α~IIb~β~3~ and α~5~β~1~ ([@bib4]; [@bib33]). In this study, we find that in addition to its regulatory role, ADMIDAS can also directly contribute to ligand binding. The γC C-terminal COOH group coordinates the ADMIDAS Ca^2+^ ion through water with strong electron density. The importance of this interaction is demonstrated by the sixfold loss in inhibitory potency of γC peptides when the C terminus is amidated.

It should be noted that the amidation experiment only demonstrates that coordination to a charged carboxyl oxygen is stronger than to a carbonyl oxygen. Both types of oxygens form direct and indirect water-mediated coordinations to Ca^2+^ ([@bib18]). Therefore, the importance of ADMIDAS coordination may extend beyond fibrinogen to include ligands with RGD sequences that are not followed by the C-terminal residue. In eptifibatide, the Arg-Gly-Asp-Trp-Pro-Cys sequence places a Pro in the same position as in the Arg-Gly-Asp-Ser-Pro sequence of fibronectin; this Pro, the bulky Trp, and cyclization place constraints on backbone conformation. Nonetheless, the Trp carbonyl oxygen in eptifibatide is in a position very similar to that of one of the two α-carboxyl oxygens of the γC and chimera peptide Val-411 residues ([Fig. 3, a--c](#fig3){ref-type="fig"}). In the absence of the constraints in the cyclic peptide, this carbonyl could move slightly and form a water-mediated coordination to the ADMIDAS similarly to the γC and RGD chimera peptide Val-411 carboxyl group. Water with weak density may be in a position to make this coordination in the eptifibatide complex structure ([Fig. 3 c](#fig3){ref-type="fig"}). Furthermore, the carbonyl oxygen of the amidated Cys two residues after the Trp forms a water-mediated coordination to the ADMIDAS ([Fig. 3 c](#fig3){ref-type="fig"}). Water-mediated ADMIDAS coordination to RGD ligands provides a plausible explanation for the finding that mutation of ADMIDAS-coordinating residues inhibits RGD-dependent binding of α~5~β~1~ to fibronectin ([@bib33]) and binding of α~IIb~β~3~ to the peptide GRGDSP ([@bib4]), although ADMIDAS mutations also appear to favor the inactive conformation of α~5~β~1~ ([@bib33]). We propose that the stimulatory effect of ADMIDAS mutations on ligand binding by integrins that do not recognize RGD, α~4~β~7~ ([@bib7]), and α~L~β~2~ ([@bib8]) reflects the regulatory role of ADMIDAS and that the inhibitory effect of ADMIDAS mutations on ligand binding by integrins that recognize RGD (or KQAGDV), α~IIb~β~3~ ([@bib4]), and α~5~β~1~ ([@bib33]) reflects a direct role of ADMIDAS in ligand recognition, in addition to a regulatory role. This proposal requires testing with further integrin--ligand crystal structures.

Evolution of the KQAGDV motif from an RGD motif in fibrinogen
-------------------------------------------------------------

Fibrinogen first evolved in vertebrates ([@bib22]). The significance of ADMIDAS coordination by the C-terminal carboxyl group of the fibrinogen γ subunit is emphasized by the fact that in vertebrates, the position of the C-terminal carboxyl group relative to the penultimate Asp residue has been invariant for the last 450 million years ([Fig. 1 b](#fig1){ref-type="fig"}; [@bib45]). Thus, the interaction with ADMIDAS of the C-terminal carboxyl group first evolved in jawless vertebrates in the context of an RGD motif and was maintained when warm-blooded vertebrates evolved the KQ(A/V)GD motif and bony fishes evolved the KQFGG(I/L)GD motif in place of the RGD motif ([Fig. 1 b](#fig1){ref-type="fig"}). Our structures also explain why in fibrinogen the residue that takes the place of the Arg in RGD is conserved as a hydrophobic residue and suggest that the three-residue insertion in bony fishes can be accommodated as a longer turn between the Lys and this hydrophobic residue.

The presence of an RGD motif in both lamprey and frog and the presence of a KQ(A/V)GDX motif in warm-blooded vertebrates and a KQFGG(I/L)GDI motif in bony fishes ([Fig. 1 b](#fig1){ref-type="fig"}) raises the possibility that evolution from the recognition of Arg to Lys occurred more than once. A plausible stepping stone in this evolutionary process is provided by the function of Lys in fibrinogen cross-linking. In lamprey as well as in higher vertebrates, fibrinogen is cross-linked within the γC peptide by the factor XIIIa transglutaminase ([@bib45]). Lys-406 is cross-linked to Gln-398 or Gln-399 in human, and the Lys N-terminal to the RGD in lamprey is cross-linked to one of the more N-terminal Gln residues ([@bib45]). *Xenopus laevis* appears similar to lamprey, with Lys and Gln residues N-terminal to the RGD. In contrast, humans, other warm-blooded vertebrates, and bony fishes resemble one another by all having the lysine that is known (human) or implicated (other species) in binding to α~IIb~β~3~ as the same lysine that is known (human) or implicated (other species) in cross-linking. In γC peptides with RGD motifs, the Lys that functions in cross-linking could later have evolved a second function in specific recognition of a platelet integrin, providing an evolutionary stepping stone from RGD-based recognition of fibrinogen by multiple integrins to Lys-based recognition of fibrinogen by a specific integrin on platelets or thrombocytes. Whether there is any more significance to the dual function of Lys-406 in human fibrinogen γ is unclear. However, there would be little, if any, competition between these two functions of Lys-406 because fibrinogen binding to platelets occurs much earlier in the clotting cascade than fibrin formation, and the fibrinogen that contributes to fibrin formation is in great excess over that bound to platelet integrin α~IIb~β~3~.

Materials and methods
=====================

The γC dodecapeptide was obtained from the American Peptide Co., and other peptides were synthesized and verified by mass spectrometry by the biopolymer facility at the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School (Boston, MA). Crystals of the α~IIb~β~3~ headpiece bound to 10E5 Fab in 11% polyethylene glycol 3350, 0.7 M magnesium acetate, and 0.1 M cacodylate, pH 6.5 ([@bib49]), were cryoprotected with a solution containing 15% polyethylene glycol 3350, 0.7 M magnesium acetate, and 0.1 M imidazole, pH 6.5, plus 5% step increases of glycerol concentration to a final 20% glycerol, and then 50 μM of synthetic peptides was added in the final cocktail. Crystals were soaked for 4 d at 4°C before freezing in liquid nitrogen. Diffraction data were collected with beamline 19ID (Advanced Photon Source) and processed with program suite HKL2000 ([@bib35]). As there is little difference in the dimensions of the unit cell compared with nonpeptide-soaked crystals, the previously determined structure of the α~IIb~β~3~ headpiece complexed with 10E5 Fab (1TXV; 2.7 Å) was directly subjected to rigid body refinement program CNS ([@bib6]) using the diffraction data. Electron density calculated using phases from the refined structure clearly showed the presence of the peptides. The peptide structures were built with program O and subjected to iterative cycles of model rebuilding in O and refinement using CNS (version 1.1) as previously described ([@bib49]).

Subsequent rebuilding with Coot and refinement with REFMAC5 ([@bib34]) resulted in structures with unusually low R~free~ ([Tables I](#tbl1){ref-type="table"} and [II](#tbl2){ref-type="table"}), which may be attributed to multiple factors. Regions for rebuilding were identified using multiple verification tools in Coot to detect structural defects supplemented with improved definition of Ramachandran outliers, clashes, and improbable rotamers using MolProbity ([@bib12]). Rebuilding first focused on the higher resolution 2.4- and 2.6-Å γC chimera deca- and dodecapeptide structures. These structures were refined in parallel so that rebuilding could focus on problems identified by verification tools or discrepancies between the model and electron density that were shared between two independent datasets. One of the shared discrepancies was a clash at α~IIb~ residue 282 accompanied by a lack of density for the putative Ala-282 Cβ atom; checking of the nucleotide sequence used for α~IIb~ expression and RefSeq entry gi88758615 reveals Gly at this position compared with Ala in UniProt entry P08514. Rebuilding of the Fab was aided by comparison with multiple high resolution V~H~, C~HI~, V~L~, and C~L~ domains that were found by BlastP search of the protein database and were individually superimposed on the 10E5 Fab. In the four γC and chimera γC peptide complexes, Fab residue Asn-157 in the light chain appears to have largely undergone deamidation with conversion to isoaspartic acid. This residue is in an Asn-Gly sequence, the sequence known to be most susceptible to deamidation ([@bib3]), and previous protein chemistry on the mouse light chain peptide containing this sequence revealed heterogeneity, suggesting chemical rearrangement ([@bib46]). The previously determined headpiece structures ([Table II](#tbl2){ref-type="table"}) did not show evidence for isoaspartic acid, which is consistent with deamidation during prolonged storage of the Fab before preparation of the more recent crystals ([Table I](#tbl1){ref-type="table"}). Although isoaspartic acid has been built in one case ([@bib15]), we did not do so because of the difficulty of implementing the correct restraints for an isopeptide bond in the peptide backbone and the mixture of products, including [l]{.smallcaps}- and [d]{.smallcaps}-aspartic acid, that result from deamidation ([@bib3]). The Xpleo server was used to guide rebuilding of several loops that were difficult to build manually ([@bib47]). Although not built in our previous headpiece structures ([@bib49]), I-EGF domain 1 residues 436--461 are clearly present, although they are less well ordered than other domains. The last disulfide-bonded loop of I-EGF1, residues 462--472, either was disordered or was removed by carboxypeptidase A, which stopped at Arg-461. Arg is known to be resistant to digestion by carboxypeptidase A ([@bib2]). Compared with our previous headpiece structures ([@bib49]), carbohydrate linkages were corrected to those known to occur in high mannose N-linked glycans; three cis-prolines were added, and one was removed. TLS refinement in REFMAC5 used groups determined with the TLS Motion Determination server ([@bib36]) and contributed a 2--3% drop in R~free~.

The γC dodecamer and decamer structures and the five previously deposited α~IIb~β~3~ headpiece 10E5 Fab complex structures ([@bib49]) were then rerefined starting with the ligands in the previous models and the headpiece-Fab moiety from the refined chimera γC decamer complex 2.4-Å structure described in [Table I](#tbl1){ref-type="table"}. Ligand topology and parameter cif files were created by the PRODRG2 server ([@bib42]). The cacodylate and eptifibatide ligands are unchanged. Use of correct chirality and flip of the peptide bond relative to the thienothiophene moiety in the L-739758 ligand and rotations around the sulfonamide N atoms in L-739758 and tirofiban result in better fits to density and hydrogen bonding to α~IIb~β~3~. The R~free~ of the five previously deposited structures is decreased by 2.1--5.1%. α~IIb~ residue 123 appears to be a true Ramachandran outlier; other outliers are in regions of poor density. All coordinates and structure factors have been deposited with the PDB. The unusually low R~free~ of the deposited structures is consistent with quality assessment by the MolProbity server ([@bib12]), which returns MolProbity scores in the 100th percentile for all nine structures (where 100th percentile is the best) compared with other deposited structures at similar resolutions.
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